利奈唑胺用于梅毒试验研究
利奈唑胺治疗早期梅毒的初步研究
The study aims to evaluate the efficacy of linezolid for the treatment of syphilis.
研究概览
详细说明
This will be a randomized, open-label, non-comparative, pilot trial to evaluate the efficacy of linezolid 600mg orally, twice a day, for ten days, using a contemporaneous historical control group benzathine penicillin G (single dose of 2.4 million units) in participants with and without HIV infection.
In total, 24 participants will be enrolled across multiple clinical sites in the United States. Participants will participate in follow-ups to monitor clinical outcomes and serological response (RPR titer) at 1 month, 3 months, and 6 months. A 5 and 10-day phone call will ensure adherence to treatment and evaluate safety.
Study findings may identify an efficacious alternative syphilis treatment to penicillin that is effective for people living with HIV. Study findings may also help address the crisis of penicillin shortages, difficulty in administration, and offer options for those with penicillin allergy.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Illinois
-
Chicago、Illinois、美国、60613
- Howard Brown Health
-
-
Mississippi
-
Jackson、Mississippi、美国、39216
- University of Mississippi Medical Center
-
Jackson、Mississippi、美国、39216
- Open Arms HealthCare Center
-
-
North Carolina
-
Greensboro、North Carolina、美国、27405
- Wake Forest Baptist Health
-
-
Rhode Island
-
Providence、Rhode Island、美国、02907
- Open Door Health
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria: To be eligible for this study, participants must be:
- Diagnosed cases of primary, secondary or early latent syphilis with RPR titer ≥1:8 within 3 weeks prior to enrollment
- 16 years of age or older
- Able to provide informed consent/assent.
- Individuals with HIV infection must be on treatment for HIV-infection and virologically suppressed (viral load < 200 copies/mL) or have a CD4 count ≥ 350 cells/mm3 as of their most recent test prior to enrollment.
Exclusion Criteria include:
- Pregnancy or a positive pregnancy test on the day of enrollment
- Patients showing signs and symptoms of neurosyphilis.
- Participants who receive certain psychotropic medications, e.g., MAO inhibitors, SNRIs, SSRIs
- Serofast RPR titer, defined as persistently positive RPR titer without more than 4-fold (2-titer level) change for 12 months or greater.
- Recent (within the past 7 days) or concomitant antimicrobial therapy with activity against syphilis, namely azithromycin, tetracycline, doxycycline, cefixime, ceftriaxone or other beta lactam antibiotics (e.g. amoxicillin)
- Individuals with HIV infection who report HIV treatment interruption for more than 4 weeks since their most recent viral load or CD4 test.
- Individuals with known myelosuppressive conditions or receiving myelosuppressive medication
- Individuals weighing 150kg (330 lbs) or more.
- Individuals with known end renal stage disease, for example individuals in hemodialysis.
- Self-reported allergy to linezolid or penicillin.
- Unwilling or unable to attend follow-up visits.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Linezolid 10 Day
Oral linezolid 600mg, taken twice a day for 10 days |
Oral Linezolid 600mg, taken twice a day for 10 days
其他名称:
|
|
有源比较器:Benzathine Penicillin G
Single intramuscular injection of 2.4 million units of benzathine penicillin G |
Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Response to Treatment
大体时间:6 months
|
Percentage of linezolid participants with a 4-fold decrease or greater in the serum RPR titer by 180 days after treatment |
6 months
|
合作者和调查者
调查人员
- 首席研究员:Jeffrey D Klausner, MD MPH、University of Southern California
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- APP-22-04165
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
No IPD will be shared with other researchers
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.